脱敏(药物)
内化
快速反应
生物
G蛋白偶联受体
兴奋剂
受体
支气管收缩
信号转导
细胞生物学
S-亚硝基化
哮喘
免疫学
药理学
生物化学
酶
半胱氨酸
作者
Fabio V. Fonseca,Thomas M. Raffay,Kunhong Xiao,Precious J. McLaughlin,Zhaoxia Qian,Zachary W. Grimmett,Naoko Adachi,Benlian Wang,Alfred Hausladen,Brian A. Cobb,Rongli Zhang,Douglas T. Hess,Benjamin Gaston,Nevin A. Lambert,James D. Reynolds,Richard T. Premont,Jonathan S. Stamler
出处
期刊:Molecular Cell
[Elsevier BV]
日期:2022-08-01
卷期号:82 (16): 3089-3102.e7
被引量:1
标识
DOI:10.1016/j.molcel.2022.06.033
摘要
The β2-adrenergic receptor (β2AR), a prototypic G-protein-coupled receptor (GPCR), is a powerful driver of bronchorelaxation, but the effectiveness of β-agonist drugs in asthma is limited by desensitization and tachyphylaxis. We find that during activation, the β2AR is modified by S-nitrosylation, which is essential for both classic desensitization by PKA as well as desensitization of NO-based signaling that mediates bronchorelaxation. Strikingly, S-nitrosylation alone can drive β2AR internalization in the absence of traditional agonist. Mutant β2AR refractory to S-nitrosylation (Cys265Ser) exhibits reduced desensitization and internalization, thereby amplifying NO-based signaling, and mice with Cys265Ser mutation are resistant to bronchoconstriction, inflammation, and the development of asthma. S-nitrosylation is thus a central mechanism in β2AR signaling that may be operative widely among GPCRs and targeted for therapeutic gain.
科研通智能强力驱动
Strongly Powered by AbleSci AI